Make a Donation

Scope

The LHCE carries out investigations at the interface of basic and clinical cancer research.

Our investigations focus on the molecular mechanisms that govern cell death and the cellular resistance to chemotherapy in hematological and non-hematological cancers. We carry out fundamental research projects and are also actively involved in the identification of promising therapeutic strategies, including novel combination strategies for extending patient survival. Important cell death pathways that are the focus of current studies include apoptosis and autophagy. Other lines of research also explore the mechanisms underlying the repair of DNA damage induced by anticancer drugs, and the role of DNA repair proteins in genomic stability and chromatin integrity. Recently, studies aiming to discover cancer protein and miRNA biomarkers in blood samples have been initiated and implemented in the laboratory in order to improve early diagnostic and treatment. 

Contact

Laboratory of Experimental Hemato-Oncology
Head of Research Unit: Dr. Guy Berchem
CRP-Santé, BAM
84, Val Fleuri, L-1526 Luxembourg
Tel: (+352) 44 11 20 84
Secretary: audrey.lemasson@crp-sante.lu
Phone: (+352) 26 970 320
Fax: (+352) 44 12 15
E-mail: berchem.guy@chl.lu

Find on Google Map

Make a Donation

ROLE OF DNA REPAIR PROTEINS IN THE REPAIR OF DNA DAMAGE INDUCED BY ANTICANCER DRUGS, GENOMIC STABILITY AND CHROMATIN INTEGRITY

‹ Back

Overview

DNA repair and epigenetic mechanisms are paramount in preventing genetic instability and aberrant gene expression, which are major driving forces in carcinogenesis. Paradoxically, DNA-damaging agents are mainstays of cancer treatment, whereas epigenetic drugs are reaching the forefront of cancer management. Understanding the molecular mechanisms that govern DNA repair and the epigenetic control of chromatin dynamics is therefore necessary for prevention of carcinogenesis and development of more effective chemotherapeutic agents.

  • Specific project 1 : Roles of DNA repair mechanisms and chromatin dynamics in the cell response to the anticancer drug cisplatin
  • Specific project 2 : Roles of human Topoisomerase IIIa (Topo IIIa) in the maintenance of telomeres